secwatch.observer — SEC 8-K summary
======================================

Issuer:     HYPERION DEFI, INC. (HYPD)
CIK:        0001682639
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001104659-24-088942
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eyenovia Q2 net loss $11.1M; plans Gen-2 Optejet submission 2025 with Mydcombi
------------------------------------------------------------------------------

- Net loss $11.1M ($0.21/share) vs $6.2M ($0.16/share) in Q2 2023; includes $2.9M MicroPine license reacquisition expense.
- Cash $2.3M at June 30; $5.8M gross equity proceeds after quarter; expects funding through Phase 3 CHAPERONE data.
- Following FDA meeting, plans Gen-2 Optejet validation in Q4 2024 and regulatory submission 2025 with Mydcombi as lead.
- Phase 3 CHAPERONE study of MicroPine; analysis expected Q4 2024.
- Mydcombi launched in 63 new offices; targeting 263 by Q3 end; dry eye collaborations with Formosa, Senju, SGN.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682639/000110465924088942/0001104659-24-088942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682639/000110465924088942/tm2421563d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-088942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer